《2011NACB糖尿病診療的指南和建議》內(nèi)容簡介

    The National Academy of Clinical Biochemistry （NACB） has developed evidence-based guidelines on topics related to the practiceof laboratory medicine. These guidelines are updated approximately every 5 years and are available on the NACB Web site （http://www.aacc.org/members/nacb）。 The NACB issued its “Guidelines and Recommendations for Laboratory Analysis in the Diagnosisand  Management  of  Diabetes  Mellitus”  in  2002  （1）。  These  recommendations  were  reviewed  and  updated  via  an  evidence-basedapproach, especially in areas in which new evidence has emerged since the 2002 publication. The process of updating guideline rec-ommendations followed the standard operating procedures for preparing, publishing, and editing NACB laboratory medicine practiceguidelines. The key steps are summarized in Fig. 1 and are explained below. The guideline-updating process was designed to fulfillthe methodological quality criteria of the Appraisal of Guidelines for Research and Evaluation （AGREE） II Instrument  （2）。

    《2011NACB糖尿病診療的指南和建議》內(nèi)容預(yù)覽

    STEP 1: Determine the Scope and Key Topics of the Guideline

    The scope and purpose of this guideline is primarily to focus on the laboratory aspects of testing in the contexts of type 1 and type2 diabetes mellitus （DM）。 It does not deal with any issues related to the clinical management of DM that are already covered inthe American Diabetes Association （ADA） or WHO guidelines. In January of each year, the ADA publishes in Diabetes Care  asupplement entitled “Clinical Practice Recommendations.” This supplement, a compilation of all ADA position statements relatedto  clinical  practice,  is  an  important  resource  for  healthcare  professionals  who  care  for  people  with  DM.  The  intention  of  theNACB guideline is to supplement the ADA guidelines and to avoid duplication or repetition of ***rmation. Therefore, it focuseson practical aspects of care to assist in making decisions related to the use or interpretation of laboratory tests during screening,diagnosing, or monitoring of patients with DM.

    STEP 2: Determine the Target Group of the Guideline and Establish a MultidisciplinaryGuideline Team

    The primary target of these recommendations includes general practitioners, physicians, nurses, and other healthcare practitionersdirectly involved in the care of diabetic patients, as well as laboratory professionals. The guidelines can be used by patients whererelevant （e.g., self-monitoring of blood glucose）， policy makers, and payers for healthcare, as well as by researchers. In addition,the guidelines may advise industry/manufacturers on how to use or develop assays for the laboratory management of DM.The guideline committee included representatives of key stakeholders to whom the recommendations are meant to apply primar-ily. Experts of the guideline team are listed in the guideline  （3） and represented the NACB （D.B. Sacks, D.E. Bruns） and the ADA（M.S. Kirkman）。 The guideline committee included clinical experts （G.L. Bakris, A. Lernmark, B.E. Metzger, D.M. Nathan） andlaboratory experts （D.B. Sacks, D.E. Bruns, M. Arnold, A.R. Horvath） whose key area of research and practice is DM. Some members

    點擊下載***：《2011NACB糖尿病診療的指南和建議》